Oral contraceptives and platelet aggregation

Shevde, Nirmala; Sussman, Ira I.; Rosner, Fred; Pacholuk, Valentina

doi:10.1016/0002-9378(78)90897-9

Cited by 16 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite this finding, considerable confusion exists regarding the effect of oral contraceptives on platelet function. Levels of platelet activation have been found to be increased (9,(11)(12)(13) or unchanged (14)(15)(16) by oral contraceptive therapy. These discrepancies may largely be explained by differences in hormonal composition of the oral contraceptives and by the varied methodology used to study platelet activation.…”

Section: Introductionmentioning

confidence: 99%

Effect of Oestrogen Dose on Whole Blood Platelet Activation in Women Taking New Low Dose Oral Contraceptives

Norris

Bonnar

1994

Thromb Haemost

View full text Add to dashboard Cite

SummaryOral contraceptive use is known to cause changes in the haemostatic system. These changes are thought to be related to oestrogen dose and to provide a possible link between the increased risk of thromboembolic disease known to occur in women taking oestrogen containing oral contraceptives. This study measured whole blood platelet activation, serially, in women taking oral contraceptives containing 20 μg and 30 μg ethinyloestradiol combined with desogestrel. Increased levels of ADP and arachidonic acid induced aggregation were observed in women taking the 30 μg ethinyloestradiol combination. Platelet release of β-thromboglobulin (βTG) was also significantly increased. Increased collagen induced aggregation was observed but this failed to reach statistical significance for the individual treatment groups. In women taking the 20 μg ethinyloestradiol combination, a significant increase was only observed when platelets were stimulated with arachidonic acid. Platelet factor 4 (PF4) levels were unchanged in both groups. Significantly higher levels of βTG were observed in women taking the 30 μg ethinyloestradiol combination compared with women taking the 20 μg ethinyloestradiol combination. These results show that oral contraceptive use is associated with platelet activation. Women taking the 20 μg ethinyloestradiol combination show less changes in platelet activation than women taking the 30 μg ethinyloestradiol combination. This lower dose pill may therefore be particularly suitable for high risk women wishing to use oral contraception.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of Oestrogen Dose on Whole Blood Platelet Activation in Women Taking New Low Dose Oral Contraceptives

Norris

Bonnar

1994

Thromb Haemost

View full text Add to dashboard Cite

show abstract

“…the studies of Shevde el al. (11) failed to notice any effect of oral contraceptives in the response of platelets to ADP, adrenaline or following diethylstilbestrol treatment in several collagen. Recent studies by Bierenbaum et al (2) showed that women on oral contraceptives had increased platelet aggregation.…”

mentioning

confidence: 99%

Enhancement of Thrombocyte Aggregation and Thromboxane B<sub>2 </sub>Synthesis by Diethylstilbestrol

1980

View full text Add to dashboard Cite

Effect of diethylstilbestrol administration on thrombocyte aggregation and thromboxane B₂ synthesis was investigated in atherosclerosis-susceptible pigeons. Platelet aggregatory response to arachidonic acid and synthesis of thromboxane B₂ from ¹⁴C-arachidonic acid was enhanced in thrombocytes derived from diethylstilbestrol-treated pigeons. Platelet total phospholipid concentration was increased in pigeons with diethylstilbestrol treatment. Enhanced thromboxane synthesis might be responsible for increased platelet aggregation, which in turn might contribute to the severe atherosclerosis noted following diethylstilbestrol treatment in several avian species.

show abstract

“…No difference in ADP-induced aggregation was observed by other workers in women using OC with low estrogen content [16,17]. The thrombotic predisposition appears to be releated to the estrogen content of OC [18,19]. Since centchroman possesses anti-estrogenic as well as weak estogenic activity [1], it seems likely that this could be responsible for its anti-aggregatory activity as well as suppression of hyperaggregatory effect.…”

Section: Discussionmentioning

confidence: 91%

Prostanoid mediated effects of centchroman, a non-steroidal oral contraceptive

et al. 1986

View full text Add to dashboard Cite

The effect of centchroman, a non-steroidal oral contraceptive, has been studied on platelet aggregation and on the products of arachidonate metabolism. Centchroman inhibited platelet aggregation in vitro and ex vivo after acute as well as chronic treatment for one year in laboratory animals. It did not affect aggregation of platelets in women taking centchroman for one year. It is an inhibitor of platelet cyclooxygenase as indicated by the inhibition of malonaldehyde and thromboxane B2 but has no effect on vascular cyclooxygenase activity ex vivo or at low concentration in vitro. Thus, centchroman is a safe antifertility agent without risk of thrombotic episodes associated with hormonal oral contraceptives.

show abstract

Oral contraceptives and platelet aggregation

Cited by 16 publications

References 15 publications

Effect of Oestrogen Dose on Whole Blood Platelet Activation in Women Taking New Low Dose Oral Contraceptives

Effect of Oestrogen Dose on Whole Blood Platelet Activation in Women Taking New Low Dose Oral Contraceptives

Enhancement of Thrombocyte Aggregation and Thromboxane B<sub>2 </sub>Synthesis by Diethylstilbestrol

Prostanoid mediated effects of centchroman, a non-steroidal oral contraceptive

Contact Info

Product

Resources

About